U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H14Cl2N2O3S
Molecular Weight 421.2987
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VISMODEGIB

SMILES

CS(=O)(=O)c1ccc(c(c1)Cl)C(=Nc2ccc(c(c2)-c3ccccn3)Cl)O

InChI

InChIKey=BPQMGSKTAYIVFO-UHFFFAOYSA-N
InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)

HIDE SMILES / InChI

Molecular Formula C19H14Cl2N2O3S
Molecular Weight 421.2987
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: http://www.ncbi.nlm.nih.gov/pubmed/24857041

Vismodegib (trade name Erivedge) is a drug for the treatment of basal-cell carcinoma (BCC). It was approved by FDA on January 30, 2012 and by the European Commission on 12 July 2013, for the treatment of adult patients with symptomatic metastatic BCC, or locally advanced BCC inappropriate for surgery or radiotherapy. The drug is also undergoing clinical trials for metastatic colorectal cancer, small-cell lung cancer, advanced stomach cancer, pancreatic cancer, medulloblastoma and chondrosarcoma as of June 2011. The substance acts as a cyclopamine-competitive antagonist of the smoothened receptor (SMO) which is part of the hedgehog signaling pathway. The Hedgehog signaling pathway plays an important role in tissue growth and repair; aberrant constitutive activation of Hedgehog pathway signaling and uncontrolled cellular proliferation may be associated with mutations in the Hedgehog-ligand cell surface receptors PTCH and SMO. SMO inhibition causes the transcription factors GLI1 and GLI2 to remain inactive, which prevents the expression of tumor mediating genes within the hedgehog pathway. This pathway is pathogenetically relevant in more than 90% of basal-cell carcinomas.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ERIVEDGE

Approved Use

ERIVEDGE capsule is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.

Launch Date

1327881600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5.95 μM
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VISMODEGIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2850 μM × h
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VISMODEGIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.3 day
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VISMODEGIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.45%
VISMODEGIB plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
170 mg/m2 1 times / day multiple, oral
Dose: 170 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 170 mg/m2, 1 times / day
Sources:
unhealthy, 11.6 years (range: 4.4–21 years)
Health Status: unhealthy
Age Group: 11.6 years (range: 4.4–21 years)
Sex: M+F
Sources:
DLT: Gamma-glutamyltransferase increased...
Dose limiting toxicities:
Gamma-glutamyltransferase increased (grade 3)
Sources:
150 mg 1 times / day multiple, oral
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 14.5 years (range: 3.9–20.3 years)
Health Status: unhealthy
Age Group: 14.5 years (range: 3.9–20.3 years)
Sex: M+F
Sources:
DLT: Hypokalemia...
Dose limiting toxicities:
Hypokalemia (grade 4)
Sources:
300 mg 1 times / day multiple, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 14.5 years (range: 3.9–20.3 years)
Health Status: unhealthy
Age Group: 14.5 years (range: 3.9–20.3 years)
Sex: M+F
Sources:
DLT: Thrombocytopenia...
Dose limiting toxicities:
Thrombocytopenia (grade 3)
Sources:
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Other AEs: Nausea, Nausea...
Other AEs:
Nausea (grade 1-2, 29.7%)
Nausea (grade 3, 0.7%)
Diarrhea (grade 1-2, 28.3%)
Diarrhea (grade 3, 0.7%)
Constipation (grade 1-2, 21%)
Vomiting (grade 1-2, 13.8%)
Fatigue (grade 1-2, 34.1%)
Fatigue (grade 3, 5.1%)
Fatigue (grade 4, 0.7%)
Weight loss (grade 1-2, 42.2%)
Weight loss (grade 3, 7.2%)
Decreased appetite (grade 1-2, 23.2%)
Decreased appetite (grade 3, 2.2%)
Muscle spasms (grade 1-2, 68.1%)
Muscle spasms (grade 3, 3.6%)
Arthralgia (grade 1-2, 15.2%)
Arthralgia (grade 3, 0.7%)
Dysgeusia (grade 1-2, 55.1%)
Ageusia (grade 1-2, 10.9%)
Alopecia (grade 1-2, 63.8%)
Hyponatremia (grade 3, 4%)
Hypokalemia (grade 3, 1%)
Azotemia (grade 3, 2%)
Sources:
540 mg single, oral
Highest studied dose
Dose: 540 mg
Route: oral
Route: single
Dose: 540 mg
Sources:
unhealthy, adult
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
pregnant
Other AEs: Birth defects...
Other AEs:
Birth defects (grade 5|severe)
Sources:
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
Other AEs: Amenorrhea...
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
Disc. AE: Metastatic malignant melanoma, Ischaemic stroke...
AEs leading to
discontinuation/dose reduction:
Metastatic malignant melanoma (grade 4, 1 patient)
Ischaemic stroke (grade 3, 1 patient)
Fatigue (grade 3, 1 patient)
Muscle spasms (grade 3, 2 patients)
Metastatic squamous cell carcinoma (grade 4, 1 patient)
Acute myocardial infarction (grade 5, 1 patient)
Dysgeusia (grade 1, 1 patient)
Weight decreased (grade 2, 1 patient)
Asthenia (grade 3, 1 patient)
Aphagia (grade 3, 1 patient)
Paraesthesia (grade 2, 1 patient)
Cellulitis (grade 3, 1 patient)
Hypovolaemic shock (grade 5, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Gamma-glutamyltransferase increased grade 3
DLT
170 mg/m2 1 times / day multiple, oral
Dose: 170 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 170 mg/m2, 1 times / day
Sources:
unhealthy, 11.6 years (range: 4.4–21 years)
Health Status: unhealthy
Age Group: 11.6 years (range: 4.4–21 years)
Sex: M+F
Sources:
Hypokalemia grade 4
DLT
150 mg 1 times / day multiple, oral
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 14.5 years (range: 3.9–20.3 years)
Health Status: unhealthy
Age Group: 14.5 years (range: 3.9–20.3 years)
Sex: M+F
Sources:
Thrombocytopenia grade 3
DLT
300 mg 1 times / day multiple, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 14.5 years (range: 3.9–20.3 years)
Health Status: unhealthy
Age Group: 14.5 years (range: 3.9–20.3 years)
Sex: M+F
Sources:
Ageusia grade 1-2, 10.9%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Vomiting grade 1-2, 13.8%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Arthralgia grade 1-2, 15.2%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Constipation grade 1-2, 21%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Decreased appetite grade 1-2, 23.2%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Diarrhea grade 1-2, 28.3%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Nausea grade 1-2, 29.7%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Fatigue grade 1-2, 34.1%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Weight loss grade 1-2, 42.2%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Dysgeusia grade 1-2, 55.1%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Alopecia grade 1-2, 63.8%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Muscle spasms grade 1-2, 68.1%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Arthralgia grade 3, 0.7%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Diarrhea grade 3, 0.7%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Nausea grade 3, 0.7%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Hypokalemia grade 3, 1%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Azotemia grade 3, 2%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Decreased appetite grade 3, 2.2%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Muscle spasms grade 3, 3.6%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Hyponatremia grade 3, 4%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Fatigue grade 3, 5.1%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Weight loss grade 3, 7.2%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Fatigue grade 4, 0.7%
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 61 years (range: 21 - 101 years)
Health Status: unhealthy
Age Group: 61 years (range: 21 - 101 years)
Sex: M+F
Sources:
Birth defects grade 5|severe
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
pregnant
Amenorrhea 3 patients
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
Dysgeusia grade 1, 1 patient
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
Paraesthesia grade 2, 1 patient
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
Weight decreased grade 2, 1 patient
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
Aphagia grade 3, 1 patient
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
Asthenia grade 3, 1 patient
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
Cellulitis grade 3, 1 patient
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
Fatigue grade 3, 1 patient
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
Ischaemic stroke grade 3, 1 patient
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
Muscle spasms grade 3, 2 patients
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
Metastatic malignant melanoma grade 4, 1 patient
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
Metastatic squamous cell carcinoma grade 4, 1 patient
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
Acute myocardial infarction grade 5, 1 patient
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
Hypovolaemic shock grade 5, 1 patient
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive
inconclusive
inconclusive
no [IC50 83.3 uM]
no
yes
yes
yes
no (co-administration study)
Comment: In vivo studies indicate that there was no clinically meaningful difference in the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, ethinyl estradiol, or norethindrone when co-administered with vismodegib.
Page: 21
yes
unlikely
Comment: The applicant states that this finding is unlikely to be of clinical relevance due to the high degree of plasma protein binding of vismodegib and the low confirmed clinical occurrence of BCRP based drug-drug interactions.
Page: 57
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes
yes
no (co-administration study)
Comment: the steady state concentrations of total and unbound vismodegib for patients taking a P-gp inhibitor concomitantly with vismodegib were within the range of concentrations of patients taking vismodegib alone.
Page: 21
yes
unlikely
Comment: Vismodegib was identified to be a substrate of CYP2C9 and CYP3A4; however, CYP inhibition would unlikely alter vismodegib concentrations because of its slow elimination via multiple pathways, including minor metabolism by several CYPs and main excretion of unchanged drug.
Page: 21
yes
unlikely
Comment: Vismodegib was identified to be a substrate of CYP2C9 and CYP3A4; however, CYP inhibition would unlikely alter vismodegib concentrations because of its slow elimination via multiple pathways, including minor metabolism by several CYPs and main excretion of unchanged drug.
Page: 21
Tox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
Up-regulation of sonic hedgehog contributes to TGF-β1-induced epithelial to mesenchymal transition in NSCLC cells.
2011 Jan 13
Effects of the Hedgehog pathway inhibitor GDC-0449 on lung cancer cell lines are mediated by side populations.
2012 Mar
The dawn of hedgehog inhibitors: Vismodegib.
2013 Jan
Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition.
2014 Jul
Patents

Sample Use Guides

150 mg orally once daily
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:51:20 UTC 2021
Edited
by admin
on Fri Jun 25 21:51:20 UTC 2021
Record UNII
25X868M3DS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VISMODEGIB
DASH   INN   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
GDC-0449
Code English
ERIVEDGE
Brand Name English
VISMODEGIB [WHO-DD]
Common Name English
VISMODEGIB [INN]
Common Name English
VISMODEGIB [VANDF]
Common Name English
2-CHLORO-N-(4-CHLORO-3-PYRIDIN-2-YL)PHENYL)-4-(METHYLSULFONYL)BENZAMIDE
Common Name English
BENZAMIDE, 2-CHLORO-N-(4-CHLORO-3-(2-PYRIDINYL)PHENYL)-4-(METHYLSULFONYL)-
Systematic Name English
NSC-755986
Code English
VISMODEGIB [USAN]
Common Name English
NSC-747691
Code English
VISMODEGIB [MI]
Common Name English
VISMODEGIB [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C2189
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
LIVERTOX 1032
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
EMA ASSESSMENT REPORTS ERIVEDGE (AUTHORIZED: CARCINOMA, BASAL CELL)
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
NDF-RT N0000184149
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
WHO-ATC L01XX43
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
WHO-VATC QL01XX43
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
Code System Code Type Description
CAS
879085-55-9
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
PRIMARY
DRUG BANK
DB08828
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
PRIMARY
DRUG CENTRAL
4227
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
PRIMARY
HSDB
8130
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
PRIMARY
EVMPD
SUB32354
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
PRIMARY
INN
9311
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
PRIMARY
MERCK INDEX
M11477
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
PRIMARY Merck Index
NDF-RT
N0000184148
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
PRIMARY Smoothened Receptor Antagonists [MoA]
PUBCHEM
24776445
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
PRIMARY
EPA CompTox
879085-55-9
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
PRIMARY
WIKIPEDIA
Vismodegib
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
PRIMARY
ChEMBL
CHEMBL473417
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
PRIMARY
RXCUI
1242987
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
PRIMARY RxNorm
IUPHAR
6975
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
PRIMARY
LACTMED
Vismodegib
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
PRIMARY
FDA UNII
25X868M3DS
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
PRIMARY
NCI_THESAURUS
C74038
Created by admin on Fri Jun 25 21:51:20 UTC 2021 , Edited by admin on Fri Jun 25 21:51:20 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
MINOR
METABOLIC ENZYME -> SUBSTRATE
MINOR
TARGET -> INHIBITOR
IC50
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC SINGLE DOSE

Volume of Distribution PHARMACOKINETIC